Valuation: Seres Therapeutics, Inc.

Market Cap 40.46M 35.28M 33.23M 30.26M 56.73M 3.88B 56.8M 398M 153M 1.97B 152M 149M 6.37B P/E 2026 *
-1.16x
P/E 2027 * -0.82x
Enterprise Value 40.46M 35.28M 33.23M 30.26M 56.73M 3.88B 56.8M 398M 153M 1.97B 152M 149M 6.37B EV / Sales 2026 *
2.93x
EV / Sales 2027 * 148x
Free-Float
88.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Seres Therapeutics, Inc.

1 day+1.75%
1 week-13.95%
Current month-17.11%
1 month-10.75%
3 months-38.43%
6 months-52.12%
Current year-72.65%
1 week 3.9
Extreme 3.9
4.84
1 month 3.9
Extreme 3.9
5.95
Current year 3.9
Extreme 3.9
16.42
1 year 3.9
Extreme 3.9
29.98
3 years 3.9
Extreme 3.9
53
5 years 3.9
Extreme 3.9
233.8
10 years 3.9
Extreme 3.9
770
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2026
Chief Executive Officer 58 31/07/2025
President 51 01/03/2026
Director TitleAgeSince
Chairman 70 01/03/2026
Director/Board Member 50 14/01/2019
Director/Board Member 80 31/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

General Counsel

-82 0.0008%
17/08/26 Sell

Director

-263 0.0027%
17/08/26 Sell

Chief Operating Officer

-64 0.0007%
Change 5-day change 1-year change 3-year change Capi.($)
+1.75%-13.95%-76.68%-92.52% 40.46M
+4.98%+5.73%+54.45%+113.83% 74.33B
-0.21%+0.86%+37.23%+81.44% 62.26B
-0.66%+6.97%+31.36%+23.45% 27.72B
+0.83%-3.43%-16.41%+359.38% 26.42B
+2.02%-0.87%+1.85%-7.92% 24.62B
-0.53%+4.65%+23.93%-11.03% 20.72B
-2.54%-3.36%+149.64%+324.48% 15.01B
-1.95%+1.80%+42.69%+165.15% 14.18B
-5.32%-8.25%-10.53%+823.50% 13.48B
Average +0.48%-0.74%+23.75%+177.98% 27.88B
Weighted average by Cap. +1.26%+2.26%+36.04%+149.09%

Financials

2026 *2027 *
Net sales 13.8M 12.03M 11.33M 10.32M 19.35M 1.32B 19.37M 136M 52.3M 673M 51.83M 50.68M 2.17B 274K 238K 225K 205K 383K 26.2M 384K 2.69M 1.04M 13.35M 1.03M 1M 43.07M
Net income -37.49M -32.69M -30.78M -28.04M -52.56M -3.59B -52.63M -369M -142M -1.83B -141M -138M -5.9B -78.95M -68.84M -64.84M -59.05M -111M -7.56B -111M -776M -299M -3.85B -297M -290M -12.43B
Net Debt - -
Logo Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. It is developing SER-155, which has shown a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT and Fast Track designation to reduce the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT. SER-155 and the Company’s other pipeline programs are designed to target multiple disease-relevant pathways. In addition to allo-HSCT, it intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically patient populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities.
Employees
66
Date Price Change Volume
21/09/26 US$4.070 +1.75% 38,807
18/09/26 US$4.000 -2.44% 95,099
17/09/26 US$4.100 -2.61% 44,425
16/09/26 US$4.210 -8.48% 83,759
15/09/26 US$4.600 -2.75% 44,825
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.070USD
Average target price
17.00USD
Spread / Average Target
+317.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MCRB Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!